Pharmafile Logo
Pharmafocus logo
Advanced Search

ipsen

Showing 15 posts of 30 posts found.

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

August 17, 2023
Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …

News

FDA accepts Ipsen’s NDA for ultra-rare genetic disorder drug

June 1, 2021
Manufacturing and Production EMA, FDA, FOP, NDA, ipsen

The FDA have accepted Ipsen’s New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist for the prevention …

News

Ipsen receives CHMP recommendation for Cabometyx in combination with Opdivo

March 1, 2021
Sales and Marketing Cancer, EMA, ipsen

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Ipsen’s Cabometyx (cabozantinib) in combination with …

News
steven_hildemann

Ipsen appoints new Exec VP and Chief Medical Officer

January 17, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen, pharma

Ipsen has named Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs …

Appointment
ipsen-logo-big

MHRA expands approval of Dysport for symptomatic treatment of focal spasticity of the upper limbs in paediatric cerebral palsy

January 6, 2020
Sales and Marketing Dysport, MHRA, ipsen, pharma

Ipsen has secured an expansion in the UK to the existing label for Dysport (lemborexant), with the Medicines and Healthcare …

News
shutterstock_168864905

Ipsen shells out $1.31bn to acquire rare disease specialist Clementia Pharmaceuticals

February 25, 2019
Sales and Marketing Clementia pharmaceuticals, acquisition, ipsen, rare disease

In a bid to boost its rare disease portfolio prospects, Ipsen has revealed its intention to acquire Clementia Pharmaceuticals, with …

News
ipsen-logo-big

Ipsen’s Cabometyx gains European approval in hepatocellular carcinoma

November 16, 2018
Medical Communications, Sales and Marketing Cabometyx, carcinoma, ipsen, pharma. European Commission

Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular …

News
mcewan

Ipsen appoints two leading R&D experts in bid to strengthen oncology arm

September 28, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, R&D, development, ipsen, oncology, research

French pharma firm Ipsen has announced the appointment of Dr. Yan Moore as Senior Vice President, Head of Oncology Therapeutic …

Appointment
shutterstock_gonnorrhea

Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer

July 5, 2018
Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma

French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …

News
kendall_square_boston

Ipsen set to relocate North American HQ to Boston

June 11, 2018
Medical Communications, Sales and Marketing biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen is set to join the ranks of a number of Boston-based biotechs, by setting up shop in Kendall Square. …

News

Ipsen receives European first-line approval for Cabometyx

May 17, 2018
Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …

News
photo_ivana_magovcevic-liebisch3

Ipsen bolsters executive leadership with two new recruits

April 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen, pharma

Ipsen is set to expand its executive leadership team with the announcement of two new recruitments: Dr Ivana Magovčević-Liebisch will …

Appointment
top_ten

Top Ten most popular articles on Pharmafile.com this week

March 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …

News
david_meek_web

Ipsen: Becoming a “development powerhouse”

March 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing David Meek, Insider Interview, ipsen, pharma

Immediately following the release of impressive full year financials, Ipsen CEO David Meek speaks on how the company is hitting …

Feature

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023